<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683564</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-BOW015-003</org_study_id>
    <nct_id>NCT02683564</nct_id>
  </id_info>
  <brief_title>BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study</brief_title>
  <official_title>A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epirus Biopharmaceuticals (Switzerland) GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epirus Biopharmaceuticals (Switzerland) GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, parallel group, multicentre global phase 3&#xD;
      clinical study to evaluate the efficacy, safety and immunogenicity of BOW015&#xD;
      (infliximab-EPIRUS) compared to Remicade in subjects with active Rheumatoid Arthritis (RA)&#xD;
      despite Methotrexate (MTX) therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) 20 clinical response</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diseases Activity Score (DAS)28 calculated with C-reactive protein (CRP)</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>54 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">548</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>BOW015</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infliximab-EPIRUS, 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Remicade (infliximab) , 3mg/kg body weight as intra venous infusion at weeks 0, 2, 6 then every 8 weeks thereafter up to Week 46.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOW015</intervention_name>
    <description>monoclonal antibody against TNF-alpha</description>
    <arm_group_label>BOW015</arm_group_label>
    <other_name>infliximab-EPIRUS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remicade</intervention_name>
    <description>monoclonal antibody against TNF-alpha</description>
    <arm_group_label>Remicade</arm_group_label>
    <other_name>infliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male and female, aged 18 to 80&#xD;
&#xD;
          2. Diagnosis of Rheumatoid Arthritis (RA) according to the revised ACR/ EULAR 2010&#xD;
             classification criteria for RA&#xD;
&#xD;
          3. Patients must have ACR/EULAR 2010 classification criteria score â‰¥ 6&#xD;
&#xD;
          4. Patients must have active disease&#xD;
&#xD;
          5. Patients must have been on treatment with methotrexate&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Prior use of infliximab, adalimumab, certolizumab, golimumab, tocilizumab, rituximab,&#xD;
             or etanercept or any other biological treatment&#xD;
&#xD;
          2. Patients with any prior or current use of anakinra and abatacept&#xD;
&#xD;
          3. Patients with suspected or confirmed current active tuberculosis (TB)&#xD;
&#xD;
          4. Patients with latent tuberculosis must start treatment for latent tuberculosis&#xD;
&#xD;
          5. Patients who have a current or past history of chronic infection with Hepatitis B,&#xD;
             Hepatitis C, or infection with Human Immunodeficiency Virus-1 or-2&#xD;
&#xD;
          6. History of completely excised and cured squamous carcinoma of the uterine cervix,&#xD;
             cutaneous basal cell carcinoma or cutaneous squamous cell carcinoma&#xD;
&#xD;
          7. History of lymphoproliferative disease&#xD;
&#xD;
          8. History or presence of any other form of malignancy&#xD;
&#xD;
          9. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,&#xD;
             hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic or cerebral&#xD;
             disease&#xD;
&#xD;
         10. History of congestive heart failure or unstable angina&#xD;
&#xD;
         11. History of any autoimmune disease other than RA&#xD;
&#xD;
         12. Major surgery within 12 weeks and planned major surgery&#xD;
&#xD;
         13. History of serious infection&#xD;
&#xD;
         14. Pre-existing central nervous system demyelinating disorders&#xD;
&#xD;
         15. Administration of live or live-attenuated vaccine within 4 weeks of screening&#xD;
&#xD;
         16. Clinically significant adverse reaction to murine or chimeric proteins&#xD;
&#xD;
         17. History or presence of any medical or psychiatric condition or disease, or clinically&#xD;
             significant laboratory abnormality&#xD;
&#xD;
         18. Participation in any clinical study of an investigational product within the previous&#xD;
             3 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>EPIRUS Clinical Development</last_name>
    <email>info@epirusbiopharma.com</email>
  </overall_contact>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

